modelVonWillebrandFactorAndCoagulatio
Extends from Pharmacolibrary.Drugs.ATC.B.B02BD06.
Information
| name: | VonWillebrandFactorAndCoagulationFactorViiiInCombination |
| ATC code: | B02BD06 | route: | intravenous |
| n-compartments | 1 |
This combination drug, marketed as human plasma-derived von Willebrand factor and coagulation factor VIII, is indicated for the treatment and prevention of bleeding episodes in patients with von Willebrand disease (VWD), a hereditary bleeding disorder. It is also used for surgical prophylaxis in patients with VWD for whom desmopressin is either ineffective or contraindicated. This product is approved and used in clinical settings today.
Pharmacokinetics
Pharmacokinetics in adult patients with severe von Willebrand disease after intravenous administration. The values reported represent mean parameters for von Willebrand factor:ristocetin cofactor activity (VWF:RCo) and factor VIII:C after administration of 80 IU/kg.
References
Øie, CI, et al., & Appa, RS (2016). High-affinity von Willebrand factor binding does not affect the anatomical or hepatocellular distribution of factor VIII in rats. Journal of thrombosis and haemostasis : JTH 14(9) 1803–1813. DOI:10.1111/jth.13406 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27378673
Franchini, M (2008). Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. Blood transfusion = Trasfusione del sangue 6 Suppl 2(Suppl 2) s33–s38. DOI:10.2450/2008.0035-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19105508
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 initial generated model